peptides for tanning
two peptides drive cosmetic tanning at the melanocortin receptors. one has an FDA approval for a rare photosensitivity disorder; the other is the community default that everyone actually uses.
the tanning conversation runs through MC1R, the melanocortin-1 receptor on melanocytes. activate it and melanocytes synthesize eumelanin, the pigment that darkens skin. melanotan-II (university of arizona, 1980s, non-selective MC1-MC5R agonist) and melanotan-I / afamelanotide (Scenesse, Clinuvel, MC1R-selective, FDA october 2019 for erythropoietic protoporphyria) both hit MC1R. PT-141 (bremelanotide, Vyleesi, FDA june 2019 for HSDD) is the MC3R/MC4R-weighted spinoff that kept the sexual-function effects and lost the tan.
the editorial position: melanotan-II is the community default for cosmetic tanning, despite no FDA approval and a real safety record of melanoma case reports and priapism. melanotan-I has the regulatory pedigree but ships as a dermatology-only 16 mg implant for EPP patients, not the bottled peptide the community actually uses.
two molecules, two regulatory paths.
the tanning effect is reproducible. the regulatory and safety conversations diverge sharply.
- melanotan-ii (tier A) — non-selective MC1-MC5R agonist. designed at university of arizona in the 1980s, abandoned by Palatin in 2000, never approved.
- melanotan-i (tier C) — afamelanotide / Scenesse. MC1R-selective. FDA-approved october 2019 (EU 2014) for erythropoietic protoporphyria.
same family, different indication.
PT-141 is the melanocortin agonist that lost the tan and kept the central nervous system effects.
- pt-141 (bremelanotide) (tier S) — Vyleesi. MC3R/MC4R-weighted melanocortin agonist. FDA-approved june 2019 (Palatin) for hypoactive sexual desire disorder in premenopausal women.
specific-question reference.
is melanotan-II FDA-approved?
no. melanotan-II is not FDA-approved for any indication. Palatin abandoned the program in 2000 in favor of PT-141. Clinuvel licensed melanotan-II in 2006, ran into regulatory resistance, and refocused on melanotan-I. melanotan-II circulates through gray-market research-peptide vendors at $20 to 50 per 10 mg vial.
what does Scenesse approve?
FDA approved Scenesse (afamelanotide / melanotan-i) in october 2019 for the increase of pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare inherited photosensitivity disorder where sunlight causes severe pain. the dose is a 16 mg subcutaneous controlled-release implant placed every two months. cost runs approximately $49,000 per implant. it is dermatology-only and is not the bottled vial the community uses.
what is the difference between melanotan-I and melanotan-II?
receptor selectivity. melanotan-I (afamelanotide) is MC1R-selective and produces tanning with a cleaner side-effect profile. melanotan-II is non-selective across MC1R through MC5R, which drives the broader effect map: tanning (MC1R), appetite suppression (MC4R), sexual arousal (MC4R), sebaceous effects (MC5R). melanotan-II is more potent at producing tan and side effects together.
how is melanotan-II related to PT-141?
PT-141 (bremelanotide / Vyleesi) is a melanotan-II derivative that Palatin developed forward when the parent compound never reached approval. the structural changes shifted the receptor selectivity toward MC3R/MC4R, dropping the tanning effect and keeping the central nervous system effects on sexual function. PT-141 is FDA-approved for HSDD in premenopausal women.
what the safety literature reports.
what melanoma signal exists for melanotan-II?
multiple published case reports document cutaneous melanoma transformation, dysplastic nevus changes, and existing-nevus darkening in melanotan-II users. a 2025 case report (Int J Oral Maxillofac Surg, PMID 40210573) documented anterior-maxilla mucosal melanoma after nasal-spray use, implicating the nasal route specifically. most cutaneous cases are attributed to combined melanotan-II use plus tanning-bed exposure rather than direct carcinogenesis, but the user-behavior pattern is real.
what side effects show up most often?
nausea (especially early doses), spontaneous erections (MC4R), facial flushing, mole darkening and new nevus formation (MC1R), appetite suppression (MC4R), and uneven pigmentation. side-effect profile is more pronounced for melanotan-II than for melanotan-I because of the non-selective receptor coverage.
does melanotan-I share the melanoma signal?
the approved Scenesse population is small (EPP affects roughly 1 in 75,000 to 200,000) and has been followed in registration trials with rigorous safety surveillance. dermatology case literature documents new mole formation and existing-nevus changes in approved use, but the cosmetic-self-injection pattern of melanotan-II is not the same population or behavior.
what about gray-market product purity?
research-peptide-vendor melanotan-II vials carry no identity or sterility assurance. independent testing has found variable peptide content and bacterial contamination in some products. the gray-market product is not the molecule the regulatory file describes.
related comparisons
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.